Hemoglobin A1c on GLP-1 therapy: what it measures, the cut points, and how often it is repeated

Hemoglobin A1c is the first number most prescribers look at before a GLP-1 prescription and the one they keep coming back to. It is simple to draw, it does not need fasting, and it answers a question no single glucose reading can: what has your blood sugar averaged over the last two to three months?

What the test measures

Glucose in the blood sticks to hemoglobin inside red blood cells. The more glucose there is, the more hemoglobin ends up glycated. Red cells live about three months, so the percentage of glycated hemoglobin reflects the average glucose over that window. The result is reported as a percentage. Some reports add an "estimated average glucose" in mg/dL next to it; that is a conversion of the same number, not a second test.

The cut points, and what they are for

MedlinePlus lists the cut points used when A1c is being used to diagnose diabetes: under 5.7% is normal, 5.7% to 6.4% is prediabetes, and 6.5% or higher is diabetes. The ADA Standards of Care use the same thresholds and add that a diagnosis normally needs a second abnormal result, from a repeat A1c or from a glucose test, unless the glucose is unmistakably high.

Those are diagnostic cut points. They are not treatment targets. For people who already have diabetes, MedlinePlus notes that many aim for under 7%, and the ADA Standards frame the target as individual: tighter for some, looser for people with limited life expectancy or a history of severe hypoglycemia. Your prescriber sets yours.

Why it matters on GLP-1 therapy

Three reasons, and they apply to different people.

It sorts you. Wegovy and Zepbound are approved for weight reduction; Ozempic and Mounjaro for type 2 diabetes. Where your A1c sits decides which label describes your situation, whether the ADA monitoring schedule applies to you, and whether glucose-lowering drugs you already take need attention.

It sets the hypoglycemia conversation. Every one of these labels warns that combining the drug with insulin or a sulfonylurea raises the risk of hypoglycemia and that the dose of those drugs may need to come down. The Wegovy label reports that in its type 2 diabetes trial, hypoglycemia (plasma glucose under 54 mg/dL) was reported in more people on Wegovy than on placebo. If your A1c says diabetes and your medication list says insulin, that conversation happens before the first injection, not after the first low.

It is the baseline. GLP-1 receptor agonists lower glucose. That is their original job. A later A1c only means something next to an earlier one from before therapy.

How often it is repeated

The ADA Standards say: at least twice a year in people who are meeting glycemic goals and have stable control, and about every three months when therapy has changed or goals are not being met. Starting a GLP-1 is a change in therapy, so most people with diabetes get an A1c about three months in. For prediabetes the Standards suggest yearly retesting. For people with a normal A1c and no diabetes, no label or guideline sets an interval; some prescribers repeat it yearly with the rest of the panel, some do not repeat it at all.

Testing more often than every three months rarely adds information. The red cells have not turned over yet.

When the number is unreliable

MedlinePlus lists the conditions that make an A1c misleading: anemia, kidney disease, liver disease, certain blood disorders such as thalassemia, and a recent blood transfusion. Certain medicines can also produce a false result. On GLP-1 therapy, the one to watch is anemia. Eating much less for months can lower iron intake, and iron deficiency changes red cell turnover in a way that nudges A1c. That is why a CBC and sometimes ferritin sit next to A1c on a follow-up panel, and why a surprising A1c is checked against a fasting glucose before anyone acts on it.

One label detail for people with retinopathy

The Ozempic, Wegovy, Mounjaro and Zepbound labels all note that rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy, and that people with a history of retinopathy should be monitored for progression. That is not a lab test; it is an eye exam. If your A1c is high and you have known retinopathy, it belongs on the same visit as the A1c discussion.

What to discuss with your prescriber

• Which category your baseline A1c puts you in, and what that means for monitoring.
• If you take insulin or a sulfonylurea: whether the dose changes at the start, and how to check glucose at home.
• When the next A1c is due, and what result would change the plan.
• Whether anything on your history (anemia, kidney or liver disease, a hemoglobin variant) makes A1c a poor measure for you, and what to use instead.

Compounded semaglutide and tirzepatide, including the products FormBlends dispenses, are not FDA approved and are not interchangeable with the brand products these labels describe. The glucose physiology is the same molecule's; the label commitments are not. For where the drugs fit in a weight program, see the FormBlends GLP-1 overview. To log your results over time, use the lab tracker.